tbuckley/cabot-search huggingface dataset:
Contralateral breast cancer risk in patients with breast cancer and a germline-<i>BRCA1/2</i> pathogenic variant undergoing radiation
Authors: Mark van Barele, Delal Akdeniz, Bernadette A M Heemskerk-Gerritsen, Nadine Andrieu, Catherine Noguès, Christi J van Asperen, Marijke Wevers, Margreet G E M Ausems, Geertruida H de Bock, Charlotte J Dommering, Encarnacion B Gómez-García, Flora E van Leeuwen, Thea M Mooij, Douglas F Easton, Antonis C Antoniou, D Gareth Evans, Louise Izatt, Marc Tischkowitz, Debra Frost, Carole Brewer, Edit Olah, Jacques Simard, Christian F Singer, Mads Thomassen, Karin Kast, Kerstin Rhiem, Christoph Engel, Miguel de la Hoya, Lenka Foretová, Anna Jakubowska, Agnes Jager, Margriet G A Sattler, Marjanka K Schmidt, Maartje J Hooning
Journal: JNCI Journal of the National Cancer Institute (2023)

Abstract Background Radiation-induced secondary breast cancer (BC) may be a concern after radiation therapy (RT) for primary breast cancer (PBC), especially in young patients with germline (g)BRCA–associated BC who already have high contralateral BC (CBC) risk and potentially increased genetic susceptibility to radiation. We sought to investigate whether adjuvant RT for PBC increases the risk of CBC in patients with gBRCA1/2-associated BC. Methods The gBRCA1/2 pathogenic variant carriers diagnosed with PBC were selected from the prospective International BRCA1/2 Carrier Cohort Study. We used multivariable Cox proportional hazards models to investigate the association between RT (yes vs no) and CBC risk. We further stratified for BRCA status and age at PBC diagnosis (&amp;lt;40 and &amp;gt;40 years). Statistical significance tests were 2-sided. Results Of 3602 eligible patients, 2297 (64%) received adjuvant RT. Median follow-up was 9.6 years. The RT group had more patients with stage III PBC than the non-RT group (15% vs 3%, P &amp;lt; .001), received chemotherapy more often (81% vs 70%, P &amp;lt; .001), and received endocrine therapy more often (50% vs 35%, P &amp;lt; .001). The RT group had an increased CBC risk compared with the non-RT group (adjusted hazard ratio [HR] = 1.44; 95% confidence interval [CI] = 1.12 to 1.86). Statistical significance was observed in gBRCA2 (HR = 1.77; 95% CI = 1.13 to 2.77) but not in gBRCA1 pathogenic variant carriers (HR = 1.29; 95% CI = 0.93 to 1.77; P = .39 for interaction). In the combined gBRCA1/2 group, patients irradiated when they were younger than or older than 40 years of age at PBC diagnosis showed similar risks (HR = 1.38; 95% CI = 0.93 to 2.04 and HR = 1.56; 95% CI = 1.11 to 2.19, respectively). Conclusions RT regimens minimizing contralateral breast dose should be considered in gBRCA1/2 pathogenic variant carriers.
Retina and RPE lipid profile changes linked with ABCA4 associated Stargardt's maculopathy
Authors: Mitra Farnoodian, Devika Bose, Francesca Barone, Luke Mathew Nelson, Marisa Boyle, Bokkyoo Jun, Khanh Do, William Gordon, Marie-Audrey Kautzmann Guerin, Rasangi Perera, Jeff X. Ji, Tiziana Cogliati, Ruchi Sharma, Brian P. Brooks, Nicolas G. Bazan, Kapil Bharti
Journal: Pharmacology & Therapeutics (2023)
K-UNN: <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" altimg="si309.svg" display="inline" id="d1e1823"><mml:mi>k</mml:mi></mml:math>-space interpolation with untrained neural network
Authors: Zhuo-Xu Cui, Sen Jia, Chentao Cao, Qingyong Zhu, Congcong Liu, Zhilang Qiu, Yuanyuan Liu, Jing Cheng, Haifeng Wang, Yanjie Zhu, Dong Liang
Journal: Medical Image Analysis (2023)
Immunological effects and safety of live rotavirus vaccination after antenatal exposure to immunomodulatory biologic agents: a prospective cohort study from the Canadian Immunization Research Network
Authors: Tiffany Fitzpatrick, Khaled Alsager, Manish Sadarangani, Anne Pham-Huy, Luis Murguía-Favela, Shaun K Morris, Cynthia H Seow, Pierre-Philippe Piché-Renaud, Tajdin Jadavji, Otto G Vanderkooi, Karina A Top, Cora Constantinescu, Juthaporn Cowan, Jeannette Comeau, Beata Derfalvi, Scott A Halperin, Catherine Burton, Sneha Suresh, Wendy Vaudry, Jane Finlay, Poonam Dharmani
Journal: The Lancet Child & Adolescent Health (2023)
Relationship Among Diabetes, Obesity, and Cardiovascular Disease Phenotypes: A UK Biobank Cohort Study
Authors: Oliver I. Brown, Michael Drozd, Hugo McGowan, Marilena Giannoudi, Marcella Conning-Rowland, John Gierula, Sam Straw, Stephen B. Wheatcroft, Katherine Bridge, Lee D. Roberts, Eylem Levelt, Ramzi Ajjan, Kathryn J. Griffin, Marc A. Bailey, Mark T. Kearney, Richard M. Cubbon
Journal: Diabetes Care (2023)

OBJECTIVE Obesity and diabetes frequently coexist, yet their individual contributions to cardiovascular risk remain debated. We explored cardiovascular disease biomarkers, events, and mortality in the UK Biobank stratified by BMI and diabetes. RESEARCH DESIGN AND METHODS A total of 451,355 participants were stratified by ethnicity-specific BMI categories (normal, overweight, obese) and diabetes status. We examined cardiovascular biomarkers including carotid intima-media thickness (CIMT), arterial stiffness, left ventricular ejection fraction (LVEF), and cardiac contractility index (CCI). Poisson regression models estimated adjusted incidence rate ratios (IRRs) for myocardial infarction, ischemic stroke, and cardiovascular death, with normal-weight nondiabetes as comparator. RESULTS Five percent of participants had diabetes (10% normal weight, 34% overweight, and 55% obese vs. 34%, 43%, and 23%, respectively, without diabetes). In the nondiabetes group, overweight/obesity was associated with higher CIMT, arterial stiffness, and CCI and lower LVEF (P &amp;lt; 0.005); these relationships were diminished in the diabetes group. Within BMI classes, diabetes was associated with adverse cardiovascular biomarker phenotype (P &amp;lt; 0.005), particularly in the normal-weight group. After 5,323,190 person-years follow-up, incident myocardial infarction, ischemic stroke, and cardiovascular mortality rose across increasing BMI categories without diabetes (P &amp;lt; 0.005); this was comparable in the diabetes groups (P-interaction &amp;gt; 0.05). Normal-weight diabetes had comparable adjusted cardiovascular mortality to obese nondiabetes (IRR 1.22 [95% CI 0.96–1.56]; P = 0.1). CONCLUSIONS Obesity and diabetes are additively associated with adverse cardiovascular biomarkers and mortality risk. While adiposity metrics are more strongly correlated with cardiovascular biomarkers than diabetes-oriented metrics, both correlate weakly, suggesting that other factors underpin the high cardiovascular risk of normal-weight diabetes.
Cell reprogramming in a predictable manner on the superhydrophobic microwell array chip
Authors: Jianan Qu, Xiaoqing Wang, Yang Zhang, Ruowen Hu, Yunqi Hao, Xuechen Zhao, Chunhui Dong, Chengxi Yang, Weirong Zhang, Jingchao Sui, Yan Huang, Peng Liu, Jian Yu, Xiaofang Chen, Yubo Fan
Journal: Biomaterials (2023)
Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial
Authors: Michael A Koren, Leyi Lin, Kenneth H Eckels, Rafael De La Barrera, Vincent Dussupt, Gina Donofrio, Erica L Sondergaard, Kristin T Mills, Merlin L Robb, Christine Lee, Oluwaseun Adedeji, Paul B Keiser, Justin M Curley, Nathanial K Copeland, Trevor A Crowell, Jack N Hutter, Melinda J Hamer, Anais Valencia-Ruiz, Janice Darden, Sheila Peel, Mihret F Amare, Tsedal Mebrahtu, Margaret Costanzo, Shelly J Krebs, Gregory D Gromowski, Richard G Jarman, Stephen J Thomas, Nelson L Michael, Kayvon Modjarrad
Journal: The Lancet Infectious Diseases (2023)
Enteroviruses and risk of islet autoimmunity or type 1 diabetes: systematic review and meta-analysis of controlled observational studies detecting viral nucleic acids and proteins
Authors: Sonia R Isaacs, Anju Roy, Brieana Dance, Emily J Ward, Dylan B Foskett, Anna J Maxwell, William D Rawlinson, Ki Wook Kim, Maria E Craig
Journal: The Lancet Diabetes & Endocrinology (2023)
Immune Checkpoint Inhibitors’ Effects on Calcified Aortic Plaques in Melanoma Survivors
Authors: Isik Turker, Sangeeta Nair, James G. Terry, Shi Huang, John Jeffrey Carr, Javid J. Moslehi, Deepak K. Gupta, Matthew R. Alexander, Douglas B. Johnson
Journal: JACC CardioOncology (2023)
How to Treat EGFR-Mutated Non–Small Cell Lung Cancer
Authors: Neel Belani, Katherine Liang, Michael Fradley, Julia Judd, Hossein Borghaei
Journal: JACC CardioOncology (2023)

• Mutations in the EGFR gene are observed in about 15% of NSCLC adenocarcinomas in the United States and are not associated with smoking. There are numerous EGFR mutations, with the most common being exon 19 deletions and the point mutation L858R in exon 21. • Osimertinib, an oral TKI, is used as the initial therapy for metastatic NSCLC harboring exon 19 deletion and exon 21 L858R mutation. Common side effects include acneiform rash, diarrhea, and paronychia. Osimertinib has also been associated with cardiomyopathy (∼1.4%-2.4%) and prolongation of the QT interval (2.7%). • In our experience, osimertinib-induced cardiomyopathy can be managed with the cessation of osimertinib and the initiation of guideline-directed therapy. Given that osimertinib is often the best available therapy, rechallenging with osimertinib often favors benefit over risk. Safe rechallenge with osimertinib is demonstrated in this case.
Anticoagulation for the Prevention of Arterial Thrombosis in Ambulatory Cancer Patients
Authors: Yan Xu, Katherine Cole, Erin Collins, Aliza Moledina, Caroline Mallity, Marc Carrier
Journal: JACC CardioOncology (2023)

The risk of arterial thrombotic events (ATEs) is high among patients on systemic anticancer therapies. Despite the efficacy of anticoagulants in the prevention of cancer-associated venous thromboembolism, it is unknown whether anticoagulation is effective to prevent ATEs.This study sought to examine the efficacy and safety of anticoagulants in ATE prevention among ambulatory cancer patients.We performed a systematic review using Medline, Embase, Scopus, and Cochrane Central Register of Controlled Trials (CENTRAL) from inception to May 21, 2022, and included studies comparing oral or parenteral anticoagulation with no anticoagulation among ambulatory patients receiving systemic anticancer therapy with no other indication for anticoagulation. The primary outcome was ATE (myocardial infarction, ischemic stroke, intra-abdominal arterial embolism, or peripheral artery occlusion). The secondary outcomes were major and nonmajor bleeding and all-cause mortality.Fourteen randomized trials involving low-molecular-weight heparins, direct oral anticoagulants, and warfarin were included. ATEs were captured as coefficacy endpoints or adverse events. Anticoagulant use was not associated with a reduction in ATEs compared with placebo or standard treatment (RR: 0.73, 95% CI: 0.50-1.04; P = 0.08; I2 = 0%). RRs of major and minor bleeding were 1.56 (95% CI: 1.12-2.17) and 2.25 (95% CI: 1.45-3.48) with anticoagulant use. In 13 trials that reported all-cause mortality, risk of death was not reduced with anticoagulants (RR: 0.99; 95% CI: 0.95-1.02; P = 0.38; I2 = 0%).Anticoagulants did not reduce ATE risk among ambulatory patients on systemic anticancer therapy and were associated with increased bleeding. Based on the current data, anticoagulants have a limited role in ATE prevention in this population as a whole.
AIE Bioconjugates for Accurate Identification and In Vivo Targeted Treatment of Bacterial Infection Based on Bioorthogonal Reaction
Authors: Yuan Fang, Xin Liu, Hanqiong Guo, Yujie Zhang, Haotian Wu, Xiao Zhou, Xiying Chen, Haijuan Qin, Heqi Gao, Yaqing Liu
Journal: Advanced Healthcare Materials (2023)

Abstract Targeted killing multidrug‐resistant bacteria with high efficiency is urgently needed for the treatment of infection with minimal collateral damage. Herein, a new near‐infrared (NIR) fluorescence nanoprobe is designed and synthesized with aggregation‐induced emission (AIE) features, which also is excellent reactive oxygen species (ROS) generator. The as‐prepared AIE nanoparticles (NPs) present outstanding sterilizing rate on methicillin‐resistant Staphylococcus aureus (MRSA) and kanamycin‐resistant Escherichia coli (KREC). Meanwhile, considering the differences in the surface structure of animal cells and bacteria, a non‐invasive image‐guided strategy for precise treatment of bacterial infection has been successfully implemented based on bioorthogonal reaction which can perform and control unnatural chemical reactions inside living organisms. The AIE NPs are thus specifically trapped on the bacterial surface while not on the normal cells, realizing real‐time tracking of the infected site distribution in vivo and guiding photodynamic therapy (PDT) for eliminating bacteria in inflammation region. That significantly improves the accuracy and sterilization rate of bacterial‐infected wounds with negligible side effects. The investigation developed a potential antibacterial agent and also provides an instructive way for targeting treatment based on bioorthogonal reaction.
Analysis of the Sport Mental Health Assessment Tool 1 (SMHAT-1) in Team USA athletes
Authors: Travis Anderson, William M Adams, Jessica D Bartley, Angel L Brutus, Amber T Donaldson, Jonathan T Finnoff
Journal: British Journal of Sports Medicine (2023)

Objective The Sport Mental Health Assessment Tool 1 (SMHAT-1) was introduced as a critical component to the athlete health evaluation. However, the effectiveness of the initial triage step questionnaire (Athlete Psychological Strain Questionnaire (APSQ)) has yet to be analysed within a National Olympic and Paralympic Committee delegation. This study evaluated the ability of the APSQ to identify athletes at risk for mental health concerns. Methods Athletes completed the APSQ and all subsequent screening questionnaires of the SMHAT-1 as part of their Tokyo and Beijing Olympic and Paralympic Games health history screening. Each questionnaire was scored according to published guidelines, and the false-negative rate (FNR) for the APSQ identifying athletes that were positively screened on the subsequent questionnaires was computed. Results 1066 athletes from 51 different Olympic and Paralympic and Summer and Winter sports completed the SMHAT-1. The FNRs for all athletes who were positively screened on a subsequent questionnaire with an APSQ score of &lt;17 ranged from 4.8% to 66.7%. The global FNR for being positively screened on any questionnaire was 67.5%. Female, Paralympic and Winter athletes scored higher on one or more questionnaires compared with male, Olympic and Summer athletes, respectively (p&lt;0.05). Conclusion Due to the high FNR of the APSQ detecting a potential mental health concern, we recommend athletes complete the APSQ and all subsequent questionnaires of the SMHAT-1 rather than using only the APSQ as an initial screening test.
Yoga-based interventions may reduce anxiety symptoms in anxiety disorders and depression symptoms in depressive disorders: a systematic review with meta-analysis and meta-regression
Authors: Javier Martínez-Calderon, María Jesús Casuso-Holgado, Maria Jesus Muñoz-Fernandez, Cristina Garcia-Muñoz, Alberto Marcos Heredia-Rizo
Journal: British Journal of Sports Medicine (2023)

Objective To summarise the effect of mind–body exercises on anxiety and depression symptoms in adults with anxiety or depressive disorders. Design Systematic review with meta-analysis and meta-regression. Data sources Five electronic databases were searched from inception to July 2022. Manual searches were conducted to explore clinical trial protocols, secondary analyses of clinical trials and related systematic reviews. Eligibility criteria Randomised clinical trials evaluating qigong, tai chi or yoga styles with anxiety or depression symptoms as the outcomes were included. No intervention, waitlist or active controls were considered as control groups. The risk of bias and the certainty of the evidence were assessed. Meta-analyses, meta-regressions and sensitivity analyses were performed. Results 23 studies, comprising 22 different samples (n=1420), were included. Overall, meta-analyses showed yoga interventions were superior to controls in reducing anxiety symptoms in anxiety disorders. Furthermore, yoga-based interventions decreased depression symptoms in depressive disorders after conducting sensitivity analyses. No differences between groups were found in the rest of the comparisons. However, the certainty of the evidence was judged as very low for all outcomes due to concerns of high risk of bias, indirectness of the evidence, inconsistency and imprecision of the results. In addition, there was marked heterogeneity among yoga-based interventions and self-reported tools used to evaluate the outcomes of interest. Conclusion Although yoga-based interventions may help to improve mental health in adults diagnosed with anxiety or depressive disorders, methodological improvements are needed to advance the quality of clinical trials in this field. PROSPERO registration number CRD42022347673.
Author correction to “YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer” [Acta Pharmaceutica Sinica B 12 (2022) 2845–2858]
Authors: Fangfang Lai, Ming Ji, Lei Huang, Yunchen Wang, Nina Xue, Tingting Du, Kai Dong, Xiaoqing Yao, Jing Jin, Zhiqiang Feng, Xiaoguang Chen
Journal: Acta Pharmaceutica Sinica B (2023)

[This corrects the article DOI: 10.1016/j.apsb.2022.02.031.].
Remote patient management of heart failure across the ejection fraction spectrum: A pre‐specified analysis of the <scp>TIM‐HF2</scp> trial
Authors: Fabian Kerwagen, Kerstin Koehler, Eik Vettorazzi, Verena Stangl, Magdalena Koehler, Martin Halle, Friedrich Koehler, Stefan Störk
Journal: European Journal of Heart Failure (2023)

The benefit of non-invasive remote patient management (RPM) for patients with heart failure (HF) has been demonstrated. We evaluated the effect of left ventricular ejection fraction (LVEF) on treatment outcomes in the TIM-HF2 (Telemedical Interventional Management in Heart Failure II; NCT01878630) randomized trial.TIM-HF2 was a prospective, randomized, multicentre trial investigating the effect of a structured RPM intervention versus usual care in patients who had been hospitalized for HF within 12 months before randomization. The primary endpoint was the percentage of days lost due to all-cause death or unplanned cardiovascular hospitalization. Key secondary endpoints were all-cause and cardiovascular mortality. Outcomes were assessed by LVEF in guideline-defined subgroups of ≤40% (HF with reduced EF [HFrEF]), 41-49% (HF with mildly reduced EF [HFmrEF]), and ≥50% (HF with preserved EF [HFpEF]). Out of 1538 participants, 818 (53%) had HFrEF, 224 (15%) had HFmrEF, and 496 (32%) had HFpEF. Within each LVEF subgroup, the primary endpoint was lower in the treatment group, i.e. the incidence rate ratio [IRR] remained below 1.0. Comparing intervention and control group, the percentage of days lost was 5.4% versus 7.6% for HFrEF (IRR 0.72, 95% confidence interval [CI] 0.54-0.97), 3.3% versus 5.9% for HFmrEF (IRR 0.85, 95% CI 0.48-1.50) and 4.7% versus 5.4% for HFpEF (IRR 0.93, 95% CI 0.64-1.36). No interaction between LVEF and the randomized group became apparent. All-cause and cardiovascular mortality were also reduced by RPM in each subgroup with hazard ratios <1.0 across the LVEF spectrum for both endpoints.In the clinical set-up deployed in the TIM-HF2 trial, RPM appeared effective irrespective of the LVEF-based HF phenotype.
Heart failure diagnosis in the general community – Who, how and when? A clinical consensus statement of the Heart Failure Association (<scp>HFA</scp>) of the European Society of Cardiology (<scp>ESC)</scp>
Authors: Kieran F. Docherty, Carolyn S.P. Lam, Amina Rakisheva, Andrew J.S. Coats, Trisha Greenhalgh, Marco Metra, Mark C. Petrie, Giuseppe M.C. Rosano
Journal: European Journal of Heart Failure (2023)

A significant proportion of patients experience delays in the diagnosis of heart failure due to the non-specific signs and symptoms of the syndrome. Diagnostic tools such as measurement of natriuretic peptide concentrations are fundamentally important when screening for heart failure, yet are frequently under-utilized. This clinical consensus statement provides a diagnostic framework for general practitioners and non-cardiology community-based physicians to recognize, investigate and risk-stratify patients presenting in the community with possible heart failure.
Freeze‐Casted Keratin Matrix as an Organic Binder to Integrate Hydroxyapatite and BMP2 for Enhanced Cranial Bone Regeneration (Adv. Healthcare Mater. 16/2023)
Authors: Wan Ting Sow, Yili Wang, Liping Chen, Qiling Lai, Qiong Chen, Linjie Chen, Chunwu Zhang, Huaqiong Li
Journal: Advanced Healthcare Materials (2023)
Boronate Building Blocks for Intracellular Protein Delivery (Adv. Healthcare Mater. 16/2023)
Authors: Qianyi Ren, Yiyun Cheng, Jia Lv
Journal: Advanced Healthcare Materials (2023)

Boronate Building Blocks Boronate building blocks have been developed for intracellular protein delivery. Article 2202049 by Qianyi Ren, Yiyun Cheng, and Jia Lv provides a summary of boronate chemistry used in the design of cytosolic protein delivery systems. The boronate building blocks can address the barriers existing in the protein delivery process.
Mesenchymal Stromal Cells Prevent Blood-induced Degeneration of Chondrocytes in a New Model of Murine Hemarthrosis
Authors: Alexandre Théron, Marie Maumus, Claire Bony-Garayt, Nicolas Sirvent, Christine Biron-Andreani, Christian Jorgensen, Danièle Noël
Journal: HemaSphere (2023)

Hemophilia is a rare congenital bleeding disorder caused by deficiency in coagulation factors VIII or IX, which is treated with prophylactic clotting factor concentrates. Nevertheless despite prophylaxis, spontaneous joint bleedings or hemarthroses still occur. The recurrent hemarthroses lead to progressive degradation of the joints and severe hemophilic arthropathy (HA) in patients with moderate and even mild forms of the disease. In absence of disease modifying treatment to stop or even delay HA progression, we aimed at evaluating the therapeutic potential of mesenchymal stromal cells (MSCs)-based therapy. We first developed a relevant and reproducible in vitro model of hemarthrosis relying on blood exposure of primary murine chondrocytes. We found that 30% whole blood for 4 days allowed to induce the characteristic features of hemarthrosis including low survival of chondrocytes, apoptosis induction, and dysregulation of chondrocyte markers in favor of a catabolic and inflammatory phenotype. We then evaluated the potential therapeutic effects of MSCs in this model using different conditions of coculture. Addition of MSCs improved the survival of chondrocytes when added either during the resolution or the acute phases of hemarthrosis and exerted a chondroprotective effect by enhancing the expression of anabolic markers, and reducing the expression of catabolic and inflammatory markers. We here provide the first proof-of-concept that MSCs may exert a therapeutic effect on chondrocytes under hemarthrosis conditions using a relevant in vitro model, thereby confirming a potential therapeutic interest for patients with recurrent joint bleedings.